Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥15,560 JPY
Change Today +440.00 / 2.91%
Volume 298.4K
As of 2:00 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ono pharmaceutical co ltd (4528) Snapshot

Open
¥15,600
Previous Close
¥15,120
Day High
¥15,680
Day Low
¥15,340
52 Week High
08/6/15 - ¥16,800
52 Week Low
10/17/14 - ¥8,650
Market Cap
1.8T
Average Volume 10 Days
349.2K
EPS TTM
¥184.14
Shares Outstanding
117.8M
EX-Date
09/28/15
P/E TM
84.5x
Dividend
¥180.00
Dividend Yield
1.16%
Current Stock Chart for ONO PHARMACEUTICAL CO LTD (4528)

Related News

No related news articles were found.

ono pharmaceutical co ltd (4528) Related Businessweek News

No Related Businessweek News Found

ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents in Japan and internationally. Its products primarily include Rivastach Patch to treat Alzheimer's disease; Glactiv and FORXIGA tablets for the treatment of type II diabetes; Emend capsules/Proemend Intravenous injection for chemotherapy-induced nausea and vomiting; Recalbon tablets to treat osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets for peripheral circulatory disorder; and Onon capsules for the treatment of bronchial asthma and allergic rhinitis. The company’s products also comprise Onon dry syrup for the treatment of bronchial asthma and allergic rhinitis; Kinedak tablets for the treatment of diabetic peripheral neuropathy; Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection for the treatment of acute lung injury associated with systemic inflammatory response syndrome; Onoact injection for the treatment of tachyarrhythmia; and ORENCIA injection for the treatment of rheumatoid arthritis. In addition, it is involved in developing drugs for various indications, such as melanoma, renal cell carcinoma, non-small cell lung cancer, bronchial asthma, allergic rhinitis, irritable bowel syndrome, glaucoma, ocular hypertension, B-cell lymphoma, underactive bladder, gastroesophageal reflux disease, Parkinson’s disease, portal hypertension, acute heart failure, head and neck carcinoma, glioblastoma, diffuse large b cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and juvenile idiopathic arthritis, as well as esophageal, ovarian, and colon cancer. Ono Pharmaceutical Co., Ltd. has drug discovery strategic alliances with Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Receptos Inc.; Xention Limited; BioFocus DPI Limited; Evotec AG; Scil Proteins GmbH; and Domain Therapeutics S.A. The company was founded in 1717 and is headquartered in Osaka, Japan.

2,913 Employees
Last Reported Date: 06/29/15
Founded in 1717

ono pharmaceutical co ltd (4528) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ono pharmaceutical co ltd (4528) Key Developments

Ono Pharmaceutical Co., Ltd. Announces Consolidated Financial Results for the First Quarter Ended June 30, 2015

Ono Pharmaceutical Co., Ltd. announced consolidated financial results for the first quarter ended June 30, 2015. For the quarter, the company reported revenue of ¥35,696 million against ¥31,808 million a year ago. Operating profit was ¥11,674 million against ¥2,777 million a year ago. Profit before tax was ¥13,208 million against ¥3,958 million a year ago. Profit for owners of the parent company was ¥9,453 million or ¥89.17 per basic share against ¥2,908 million or ¥27.43 per basic share a year ago. Profit for the period was ¥9,841 million compared with ¥2,956 million a year ago. Net cash used in operating activities was ¥1,891 million against ¥800 million a year ago. Purchases of property, plant and equipment was ¥566 million against ¥1,609 million a year ago. Purchases of intangible assets were ¥228 million against ¥8,777 million a year ago.

Ono Pharmaceutical Co., Ltd. to Report Q1, 2016 Results on Aug 04, 2015

Ono Pharmaceutical Co., Ltd. announced that they will report Q1, 2016 results on Aug 04, 2015

Ono Pharmaceutical Co., Ltd. Proposes Dividend Payable on June 29, 2015

Ono Pharmaceutical Co., Ltd. at the ordinary general shareholders meeting to be held on June 26, 2015 to propose total amount of allocation ¥90 per share of common stock Total dividend amount of ¥9,541,792,620. Effective date of the distribution of the dividend June 29, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4528:JP ¥15,560.00 JPY +440.00

4528 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4528.
View Industry Companies
 

Industry Analysis

4528

Industry Average

Valuation 4528 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONO PHARMACEUTICAL CO LTD, please visit www.ono.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.